Figures
Abstract
Objectives
MicroRNA-7 (miR-7) is highly connected to cancerous cell proliferation and metastasis. It is also involved in myocardial ischemia-reperfusion (I/R) injury and is upregulated in cardiomyocyte under simulated I/R (SI/R). We aimed to investigate the role of miR-7 during myocardial I/R injury in vitro and in vivo and a possible gene target.
Methods and Results
Real-time PCR revealed that miR-7a/b expression was upregulated in H9c2 cells after SI/R. Flow cytometry showed SI/R-induced cell apoptosis was decreased with miR-7a/b mimic transfection but increased with miR-7a/b inhibitor in H9c2 cells. In a rat cardiac I/R injury model, infarct size determination and TUNEL assay revealed that miR-7a/b mimic decreased but miR-7a/b inhibitor increased cardiac infarct size and cardiomyocyte apoptosis as compared with controls. We previously identified an important gene connected with cell apoptosis -- poly(ADP-ribose) polymerase (PARP) -- as a candidate target for miR-7a/b and verified the target by luciferase reporter activity assay and western blot analysis.
Citation: Li B, Li R, Zhang C, Bian H-j, Wang F, Xiao J, et al. (2014) MicroRNA-7a/b Protects against Cardiac Myocyte Injury in Ischemia/Reperfusion by Targeting Poly(ADP-Ribose) Polymerase. PLoS ONE 9(3): e90096. https://doi.org/10.1371/journal.pone.0090096
Editor: Sebastian Grundmann, University Heart Centre Freiburg, Germany
Received: July 25, 2013; Accepted: January 31, 2014; Published: March 3, 2014
Copyright: © 2014 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the the National Natural Science Foundation of China [81070087], and the National 973 Basic Research Program of China [2012CB722406].the URL of any funder's website:http://isisn.nsfc.gov.cn/egrantweb/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
MicroRNAs (miRNAs) are single-stranded, small noncoding RNAs [1]–[3] that negatively regulate gene expression via degradation or translational inhibition of their target mRNAs [4]–[7] at the post-transcriptional level [8]–[10]. miRNAs play an important role in myocardial ischemia-reperfusion (I/R) injury [11]–[17]. For example, ectopic expression of miR-144 and -451 augmented cardiomyocyte survival, which was further improved by overexpression of miR-144/451 in response to simulated myocardial I/R injury [12]. Knockdown of endogenous miR-320 protects against I/R-induced cardiomyocyte death and apoptosis by targeting heat shock protein 20 (Hsp20) [13]. miR-494 targets both proapoptotic and antiapoptotic proteins for cardioprotective effects against I/R-induced injury by activating the Akt pathway [15].
As the most abundant homologue of the poly(ADP-ribose) polymerase (PARP) family [18], PARP-1 is an affluent nuclear enzyme and plays a pivotal role in DNA repair, regulation of cytoskeletal organization, expression of various proteins and genes, and apoptosis [19]. As the substrate of caspase-3, the 116-kDa nuclear PARP is cleaved into an 89-kDa apoptotic fragment during cell apoptosis [20]; The activation of caspase-3 and proteolytic cleavage of PARP are considered major executioners of apoptosis [21]. Heart I/R injury triggers apoptotic cell death by activating a caspase cascade and cleavage of PARP, and inhibition of PARP can promote cell and tissue survival and reduce cell apoptosis.
miR-7, as a tumor suppressor, reduces proliferation and increases apoptosis of tumour cells such as in malignant neuroblastomas, lung cancer and tongue squamous cell carcinoma [22]–[26]. However, the role of miR-7a/b in cardiac I/R injury has rarely been reported. Microarray assay revealed that miR-7 was upregulated in murine hearts after I/R [13]. In this study, we detected the expression of miR-7a/b with real-time PCR and investigated its role during myocardial I/R injury in vivo and investigated its role during myocardial I/R injury in vivo and a possible target.
Methods
Cell culture
H9c2 (rat ventricular cell line) and HEK293 (human embryonic kidney cell line) cells were obtained from the American Type Culture Collection (Manassas, VA). The cells were cultured at 37°C under 5% CO2 in Dulbecco modified Eagle medium (DMEM) containing 10% fetal bovine serum (Invitrogen-Gibco) and 100 µg/ml penicillin/streptomycin.
Simulated ischemia/reperfusion (SI/R)
At 48 h after transfection with miR-7a/b mimic or inhibitor (see below), H9c2 cells were subjected to SI/R. Specifically, the medium was replaced by serum- and glucose-deficient DMEM [27], and cells were placed into a hypoxic chamber at 37°C for 10 h, then were reoxygenated for 2 h with DMEM containing 10% fetal bovine serum.
Cardiac I/R animal model
The animal experiments conformed to the Animal Management Rules of the Chinese Ministry of Health (document No. 55, 2001) and were approved by the Animal Care Committee of Shandong University. Female Wistar rats (12–16 weeks old, from Shandong University) were housed in an animal holding facility under standard light (alternating 12 h light/dark cycles), temperature (22°C±0.5°C) and humidity (60%±10%) for at least 1 week before experiments. Rats were randomly divided into 7 groups for treatment (n = 16 each): 1) sham control; 2) I/R: the left anterior descending branch (LAD) was occluded for 30 min and reperfused for 2 h; 3) I/R+GFP: I/R after injection of lentivirus vector with a GFP reporter into the rat myocardium [28] as a negative control for 7 days; 4,5) I/R+miR-7a/b mimic: IR after injection of lentivirus vector with miR-7a/b mimic into the rat myocardium for 7 days; 6,7) I/R+miR-7a/b inhibitor: I/R after injection of lentivirus vector with miR-7a/b inhibitor into the rat myocardium for 7 days.
For the I/R procedure, rats were anesthetized with sodium pentobarbital (50 mg/kg intraperitoneally). The trachea was cannulated with a PE-90 catheter, and artificial respiration was provided by a respirator with fraction of inspired oxygen (FiO2) 0.80, frequency 100 strokes/min and tidal volume 0.8 to 1.2 mL to maintain normal partial pressure of O2, partial pressure of CO2 and pH. The heart was exposed by left thoracotomy in the fourth intercostal space. The I/R model was induced with a 4–0 silk suture ligating LAD to block blood flow. After 30 min of ischemia, the knot was relaxed and the heart was allowed to reperfuse for 2 h. Rats were then killed. Sham control animals underwent the entire surgical procedure and the silk suture was passed beneath the coronary artery, but the LAD was not ligated.
Infarct size determination
At the end of reperfusion, the rat LAD coronary artery was re-occluded and Evans blue dye solution (3 mL, 2% wt/vol) was injected into the left ventricle to identify ischemia (area at risk [AAR]) and non-ischemia (area not at risk). Then hearts were harvested and rinsed in normal saline. Tissues were semi-frozen for 30 min at −20°C, then the left ventricle was isolated and transversely cut into slices (1 mm thick). Slices were perfused with 1% triphenyltetrazolium chloride (Sigma) at 37°C for 15 min to distinguish ischemic and infarcted tissue. Non-infarcted areas with blue staining were designated as viable, and infarcted areas without staining were designated as non-viable. Finally, after the areas of the ventricle were weighed separately, the AAR and infarct size were calculated, and the infarct size was expressed as a percentage of the AAR [29].
MiRNA transfection
The miR-7a/b mimic sequences were designed as follows: 5′-UGGAAGACUAGUGAUUUUGUUGU-3′/5′- UGGAAGACUUGUGAUUUUGUUGU-3′. The miR-7a/b inhibitor sequences were designed as follows: 5′-ACAACAAAAUCACUAGUCUUCCA-3′/5′- ACAACAAAAUCACAAGUCUUCCA-3′. The scramble control miRNA was synthesized with the following sequence: 5′-UUCUCCGAACGUGUCACGUTT-3′. The anti-microRNA control sequence was 5′-CAGUACUUUUGUGUAGUACAA-3′. All sequences were obtained from Genepharma (Shanghai). H9c2 cells were seeded at 1×106 per 100-mm plate overnight until 50% confluence. For 1×106 cells, 0.4 nmol miR-7a/b mimic or inhibitor was mixed with 5.0 µl Lipofectamine 2000 (Invitrogen, USA) and transfected into cells following the manufacturer's instructions. After 6 h, the supernatant was removed and fresh medium was added. Cells were cultured for another 48 h before further experiments [30].
Quantitative RT-PCR
Total RNA including miRNA was isolated with TRIzol reagent (Invitrogen) according to the manufacturer's instructions. cDNA synthesis involved use of the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) with RT-U6 and miRNA-specific stem-loop primers. miR-7a/b levels were measured by use of Taqman MicroRNA assays (Applied Biosystems) and Taqman Universal PCR Master Mix (Applied Biosystems). For PARP mRNA quantification, cDNA synthesis was performed with Oligo(dT). Quantitative RT-PCR analysis was performed with a SYBR RT-PCR kit (Takara). The comparative Ct (threshold cycle) value was used for measurement with U6 and β-actin as an internal control.
Western blot analysis
Equal amounts of protein were isolated from cultured H9c2 cells and western blot analysis was performed with the anti-PARP antibody (dilution 1∶1000; 116 and 89 kDa) and anti-caspase-3 antibody (1∶1000; 35 and 17 kDa; both Cell Signaling Technology, USA). Immunoreactive bands were visualized by use of an enhanced chemoluminescence kit (Millipore, USA) and quantified by use of Image-Pro Plus 6.0.
Flow cytometry
After SI/R, H9c2 cells were collected and resuspended in 1× binding buffer, then these cells were stained with antibody to Annexin V-FITC and propiduim iodide (BD Biosciences, Franklin Lakes, NJ) according to the manufacturer's instructions. The percentage of apoptotic cells was quantified by flow cytometry (BD, USA).
Luciferase assay
After miR-7a/b mimic was transfected into HEK293 cells, GV126-PARP-3′-UTR-WT (wild type)/MU (mutant type) vectors expressing firefly luciferase and pRL-cmv vectors expressing renilla luciferase (Genechem,Shanghai) were cotransfected into cells by use of Lipofectamine 2000 (Invitrogen). Luciferase activity was measured with the Dual-Luciferase Reporter Assay System (Promega) and renilla luciferase activity was an internal control.
Terminal deoxynucleotidyltransferase-mediated dUTP nick end labelling (TUNEL)
We used TUNEL assay to evaluate apoptotic activity by DNA breakage. Rat heart sections were deparaffinized and rehydrated with serial changes of xylene and ethanol, then preprocessed with freshly prepared permeabilisation solution containing 0.1% Triton X–100 and 0.1% sodium citrate for 15 min for optimal proteolysis. Apoptosis was detected with an apoptosis detection kit (Roche, Germany). The TdT reaction was carried out for 1 h at 37°C in a humidified chamber, and sections were stained with DAPI for nuclei. TUNEL-positive cells were counted in a random selection of 10 fields and expressed as a percentage of normal nuclei [31] under confocal laser microscopy.
Results
miR-7a/b expression upregulated by SI/R in H9c2 cells
To identify the potential effect of miR-7a/b in myocardial I/R injury, we measured the expression of miR-7a/b in H9c2 cells after 10 h hypoxia and 2 h reoxygenation (SI/R). As compared with controls, the level of miR-7a/b was increased by 2.5- and 2.46-fold, respectively, after SI/R (P<0.01, Fig. 1A,B). Therefore, miR-7a/b may play an important role in SI/R of H9c2 cells.
H9c2 cells underwent hypoxia for 10(A) Expression of miR-7a. (B) Expression of miR-7b. N = 9, *P<0.01 vs. control.
miR-7a/b directly targeted PARP and downregulated PARP protein expression in H9c2 cells
To illuminate the function of miR-7a/b in H9c2 cells, we synthesized the sequences of miR-7a/b mimic and inhibitor and detected their efficiency after tansfection. The expression of miR-7a/b was greatly increased after transfection with miR-7a/b mimic, but decreased after transfection with miR-7a/b inhibitor for 48 h in H9c2 cells as compared with controls (P<0.01, Fig. 2A, B).
(A,B) qRT-PCR of the efficiency of transfection of miR-7a/b mimic or inhibitor. N = 9, *P<0.01 vs. the control. (C) Conserved miR-7a/b binding site in 3′ untranslated region (UTR) of PARP. WT: wild type; MU: mutant type. (D, E) After miR-7a/b mimic or negative control miRNA was transfected into HEK293 cells, luciferase reporters were cotransfected into HEK293 cells for 48 h. Luciferase activity was measured and was normalized to that of Renilla. N = 6, *P<0.01, #P>0.05 vs. control. (F, G) Western blot analysis of protein level of PARP and caspase-3 with miR-7a/b mimic or inhibitor transfected into H9c2 cells. N = 3, *P<0.01 vs. control. NS, not significant.
To elucidate the molecular mechanisms of miR-7a/b in SI/R injury of cardiomyocyte, we used TargetScan, the miRNA target prediction program (http://www.targetscan.org/), to screen putative targets and found that PARP had conserved binding sites for miR-7a/b (Fig. 2C). To confirm whether miR-7a/b targeted PARP through its 3′ untranslated region (UTR), the 3′ UTR segment of PARP mRNA harboring the putative miR-7a/b binding sequence was cloned into a firefly luciferase reporter plasmid (GV126-PARP 3′-UTR-WT), and a mutant luciferase reporter vector was constructed with the miR-7a/b binding site mutated (GV126-PARP 3′-UTR-MU) (Fig. 2C). After miR-7a/b mimic or negative control miRNA transfection into HEK293 cells, luciferase reporters were cotransfected for 48 h. Transfection with the miR-7a/b mimic strongly inhibited luciferase activity of the GV126-PARP 3′-UTR-WT (P<0.01, Fig. 2D), but not the GV126-PARP 3′-UTR-MU (P>0.05, Fig. 2E). Therefore, miR-7a/b directly targeted PARP.
To further verify whether miR-7a/b targets PARP under physiological conditions and inhibits endogenous PARP expression, we transfected miR-7a/b mimic or inhibitor into H9c2 cells, and measured the protein expression of PARP. The expression of PARP was downregulated with miR-7a/b mimic (P<0.01, Fig. 2F) and upregulated with miR-7a/b inhibitor (P<0.01, Fig. 2G). However, the expression of caspase-3 was not changed with miR-7a/b mimic or inhibitor transfection(P>0.05, Fig. 2F, G). Thus, miR-7a/b may directly target and inhibit PARP protein expression in H9c2 cells.
Overexpression of miR-7a/b protected H9c2 cells and reduced SI/R-induced cell apoptosis
Because miR-7a/b expression was upregulated by SI/R in H9c2 cells, we wondered whether miR-7a/b protected cardiomyocyte against SI/R-induced cell apoptosis. Flow cytometry revealed greater apoptosis with SI/R than control treatment in H9c2 cells. (P<0.01, Fig. 3A, B). Transfection with miR-7a/b mimic decreased the apoptosis rate (P<0.01, Fig. 3A) and Transfection with miR-7a/b inhibitor increased the rate as compared with SI/R alone (P<0.01 and P<0.05, Fig. 3B). Thus, overexpression of miR-7a/b protected H9c2 cells against SI/R-induced apoptosis.
(A, B) Cells were stained with antibody to Annexin V-FITC and propiduim iodide after transfection with miR-7a/b mimic or inhibitor; Representative flow cytometry of apoptosis of cardiomyocyte under different conditions. N = 9, *P<0.01 vs. control; ▴P<0.01, $P<0.05 vs. SI/R. NS, not significant. (C, D) Western blot analysis of the protein level of intact and cleaved fragments of PARP and caspase-3. Before SI/R, cardiomyocyte were transfected with miR-7a/b mimic or inhibitor, respectively. N = 3, *P<0.01 vs. control; ▴P<0.01, P<0.05 vs. SI/R.
To further investigate the mechanism of miR-7a/b protecting against cardiomyocyte apoptosis in SI/R, we transfected miR-7a/b mimic or inhibitor into H9c2 cells and evaluated the protein level of PARP and caspase-3. After SI/R, the level of intact 35-kDa caspase-3 was reduced and that of the 17-kDa cleaved fragment was increased (P<0.01, Fig. 3C, D). As the substrate of caspase-3, the 116-kDa PARP was cleaved into an 89-kDa fragment (P<0.01, Fig. 3C, D). The increased levels of cleaved PARP and caspase-3 are a hallmark of apoptosis. Under SI/R, transfection with miR-7a/b mimic significantly inhibited the protein expression of 116-kDa PARP and reduced the levels of cleaved PARP and caspase-3 as compared with SI/R alone (P<0.01 for both, Fig. 3C). In contrast, miR-7a/b inhibitor increased the protein expression of 116-kDa PARP and augmented the levels of cleaved PARP and caspase-3 as compared with SI/R alone (P<0.01 for both, Fig. 3D). Therefore, PARP is a functional gene target involved in miR-7a/b–mediated cardiomyocyte protection against SI/R-induced cell apoptosis.
miR-7a/b inhibited PARP expression and decreased cardiac infarct size and myocardial cell apoptosis after I/R in vivo
We showed that miR-7a/b targets PARP in vitro, so we investigated whether miR-7a/b targeted PARP and inhibited PARP expression in vivo. The lentivirus with miR-7a/b mimic or inhibitor was injected into the rat myocardium. After successful induction of I/R in rats, the expression of PARP was decreased as compared with sham controls (P<0.01, Fig. 4A, B). PARP was downregulated with miR-7a/b mimic and upregulated with miR-7a/b inhibitor as compared with I/R+GFP (P<0.01, Fig. 4A, B). Thus, miR-7a/b may directly target and inhibit PARP expression in rat hearts.
qRT-PCR analysis of the mRNA expression of PARP after transfection of (A) miR-7a/b mimic and (B) miR-7a/b inhibitor during I/R. N = 8, *P<0.01 vs. sham; #P<0.01 vs. I/R+GFP. NS, not significant.
To further study the biological role of miR-7a/b after I/R, we evaluated the extent of AAR and myocardial infarct size in the rat I/R injury model. Overexpression of miR-7a/b significantly reduced the infarct size (P<0.01, Fig. 5A) and AAR (P<0.05, Fig. 5B) as compared with I/R+GFP. Conversely, inhibition of miR-7a/b increased the infarct size and AAR as compared with I/R+GFP (P<0.01, Fig. 5A, B). Additionally, as a biochemical marker of myocardial cell necrosis, after I/R, LDH release was significantly suppressed with miR-7a/b mimic treatment but increased with miR-7a/b inhibitor treatment as compared with I/R+GFP (P<0.01, Fig. 5C).
(A, B, C) Effect of miR-7a/b mimic and inhibitor on I/R-induced (A) infarct size, (B) area at risk, and (C) lactate dehydrogenase (LDH) release. LV, left ventricle. N = 8. *P<0.01 vs. sham; ▴P<0.01, $P<0.05 vs. I/R+GFP. (D) Representative photomicrographs and quantification of ventricular tissue with TUNEL staining under different conditions with miR-7a/b mimic or inhibitor treatment. N = 8. *P<0.01 vs. sham; ▴P<0.01 vs. I/R+GFP. DAPI, nuclei staining. NS, not significant.
To investigate the anti-apoptotic effect of miR-7a/b in I/R-altered myocardial cells in vivo, we performed TUNEL assay of rat heart tissue. After I/R, the rate of cell apoptosis was significantly increased as compared with sham controls (P<0.01, Fig. 5D). miR-7a/b mimic treatment attenuated this increase but inhibitor treatment exacerbated this increase as compared with I/R+GFP (P<0.01, Fig. 5D). Therefore, overexpression of miR-7a/b decreased the cardiac infarct damage and reduced I/R-induced myocardial cell apoptosis after I/R in vivo in rats.
Discussion
Here, we investigated the role of miR-7 during myocardial I/R injury in vitro and in vivo. miR-7a/b was upregulated in H9c2 cells after 10 h hypoxia and 2 h reoxygenation and directly targeted and inhibited the expression of PARP in vitro and in vivo. Overexpression of miR-7a/b by miR-7a/b mimic reduced SI/R-induced cell apoptosis in vitro, and transfection of a lentivirus with miR-7a/b mimic significantly decreased cell apoptosis and cardiac infarct size in a rat I/R injury model. Therefore, overexpression of miR-7a/b reduced myocardial cell apoptosis in rat I/R injury by negatively regulating its target gene, PARP.
MiRNAs are small, non-coding RNAs that play an important role in the regulation of gene expression [32]. A growing body of evidence shows that miRNAs play a pivotal role in heart diseases [1], [33]–[34]. Some miRNAs are associated with cardiomyocyte I/R injury. For example, miR-1 enhances cardiomyocyte apoptosis by regulating the target genes Hsp60 and Hsp70, whereas miR-133 targets and represses caspase-9 expression to decrease cardiomyocyte apoptosis [35]. miR-320 was downregulated after I/R in murine hearts, and knockdown of miR-320 reduced I/R-induced cardiomyocyte apoptosis by suppressing Hsp20 [13]. miR-499 inhibited cardiomyocyte apoptosis in I/R; the putative targets of miR-499 are α and β isoforms of the calcineurin catalytic subunit, and miR-499 protected cardiomyocyte by suppressing calcineurin-mediated dephosphorylation of dynamin-related protein 1 [36]. An adenovirus expressing miR-21 delivered into rat hearts improved left ventricular remodeling and decreased myocardial cell apoptosis in I/R injury [17]. Under hypoxia, miR-199a inhibited hypoxia-inducible-factor 1α (HIF-1α) expression and reduced cardiomyocyte apoptosis. Knockdown of miR-199a during normoxia upregulated the expression of HIF-1α and Sirtuin-1 and induced hypoxia preconditioning [37]. In our studies, the expression of miR-7a/b was sensitive to SI/R in H9c2 cells: after 10 h hypoxia and 2 h reoxygenation, the expression of miR-7a/b was increased by about 2.50-fold as compared with controls. Therefore, miR-7a/b is an I/R-related miRNA in rat cardiomyocyte.
Furthermore, we investigated the potential role of miR-7a/b in I/R-induced myocardial cell injury. Previous studies have confirmed that miR-7 inhibits cell proliferation and increases cell apoptosis in some cancers [23]–[26]. However, whether miR-7a/b is involved in I/R-induced cardiomyocyte apoptosis was not clear. We found that overexpression of miR-7a/b significantly decreased and inhibition of it increased SI/R-induced cell apoptosis in vitro. Thus, miR-7a/b may protect cardiomyocyte against I/R injury at the cellular level. These effects were further confirmed in vivo after I/R injury with transfection of a lentivirus with miR-7a/b mimic or inhibitor into the rat myocardium. Overexpression of miR-7a/b decreased and its inhibition increased cardiomyocyte apoptosis, myocardial infarct size, AAR and LDH release. Therefore, overexpression of miR-7a/b may protect rat cardiomyocyte against I/R injury in vivo and in vitro.
MiRNAs enforce their function via degradation or translational inhibition of their target mRNAs [4]–[7] at the post-transcriptional level [8]–[10]. PARP, as a substrate of caspase-3, is closely related to cell apoptosis. We used an miRNA target prediction program and predicted miR-7a/b binding sites at the 3′ UTR of PARP. Transfection with miR-7a/b mimic significantly reduced the luciferase activity of GV126-PARP-3′-UTR-WT. Furthermoreapp:addword:furthermore, in in vivo and in vitro experiments, transfection with miR-7a/b mimic significantly inhibited but miR-7a/b inhibitor substantially increased the expression of PARP. Therefore, PARP is a functional target gene of miR-7a/b involved in miR-7a/b–mediated cardiomyocyte protection against I/R.
PARP is a substrate for caspase-3, a key protease during apoptosis [38], and cleaved PARP is an important marker for apoptosis [39]. We found the expression of cleaved PARP remarkably reduced after transfection with miR-7a/b mimic in H9c2 cells during SI/R as compared with SI/R alone. In contrast, inhibition of miR-7a/b increased the expression of cleaved PARP as compared with SI/R alone. The expression pattern for cleaved caspase-3 was similar to that of cleaved PARP. Activated caspase-3 weakens the function of DNA repair [19], causing cells to exhibit typical characteristics of apoptosis, including nuclear changes, chromatin condensation, and DNA fragmentation [40]. Therefore, overexpression of miR-7a/b may be responsible for decreasing cell apoptosis and protecting cardiomyocyte during I/R injury.
Conclusions
Our findings reveal that miR-7a/b is sensitive to SI/R in cardiomyocyte, and overexpression of miR-7a/b protects cardiomyocyte against I/R-induced apoptosis in vitro and in vivo. PARP may be the target gene of miR-7a/b against I/R-mediated cardiomyocyte apoptosis. miR-7a/b may be a potential drug target for treating cardiomyocyte I/R injury.
Author Contributions
Conceived and designed the experiments: BL XPJ GHS YZ. Performed the experiments: BL RL FW JX SWL CZ. Analyzed the data: BL HJB WY CZ. Contributed reagents/materials/analysis tools: BL MXZ SXW. Wrote the paper: BL XPJ.
References
- 1. van Rooij E, Olson EN (2007) MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 117: 2369–2376.
- 2. Latronico MV, Catalucci D, Condorelli G (2007) Emerging role of microRNAs in cardiovascular biology. Circ Res 101: 1225–1236.
- 3. Callis TE, Wang DZ (2008) Taking microRNAs to heart. Trends Mol Med 14: 254–260.
- 4. Ambros V (2003) MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 113: 673–676.
- 5. Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, et al. (2005) The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310: 1817–1821.
- 6. Pasquinelli AE, Hunter S, Bracht J (2005) MicroRNAs: a developing story. Curr Opin Genet Dev 15: 200–205.
- 7. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.
- 8. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, et al. (2006) Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev 20: 2202–2207.
- 9. Newman MA, Thomson JM, Hammond SM (2008) Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 14: 1539–1549.
- 10. Viswanathan SR, Daley GQ, Gregory RI (2008) Selective blockade of microRNA processing by Lin28. Science 320: 97–100.
- 11. Ye Y, Hu Z, Lin Y, Zhang C, Perez-Polo JR (2010) Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res 87: 535–544.
- 12. Zhang X, Wang X, Zhu H, Zhu C, Wang Y, et al. (2010) Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death. J Mol Cell Cardiol 49: 841–850.
- 13. Ren XP, Wu J, Wang X, Sartor MA, Qian J, et al. (2009) MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 119: 2357–2366.
- 14. Tang Y, Zheng J, Sun Y, Wu Z, Liu Z, et al. (2009) MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. Int Heart J 50: 377–387.
- 15. Wang X, Zhang X, Ren XP, Chen J, Liu H, et al. (2010) MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. Circulation 122: 1308–1318.
- 16. Xiao J, Zhu X, He B, Zhang Y, Kang B, et al. (2011) MiR-204 regulates cardiomyocyte autophagy induced by ischemia-reperfusion through LC3-II. J Biomed Sci 18: 35.
- 17. Qin Y, Yu Y, Dong H, Bian X, Guo X, et al. (2012) MicroRNA 21 inhibits left ventricular remodeling in the early phase of rat model with ischemia-reperfusion injury by suppressing cell apoptosis. Int J Med Sci 9: 413–423.
- 18. Zhou HZ, Swanson RA, Simonis U, Ma X, Cecchini G, et al. (2006) Poly(ADP-ribose) polymerase-1 hyperactivation and impairment of mitochondrial respiratory chain complex I function in reperfused mouse hearts. Am J Physiol Heart Circ Physiol 291: H714–723.
- 19. Zhao YJ, Wang JH, Fu B, Ma MX, Li BX, et al. (2009) Effects of 3-aminobenzamide on expressions of poly (ADP ribose) polymerase and apoptosis inducing factor in cardiomyocytes of rats with acute myocardial infarction. Chin Med J (Engl) 122: 1322–1327.
- 20. Duan H, Orth K, Chinnaiyan AM, Poirier GG, Froelich CJ, et al. (1996) ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. J Biol Chem. 271: 16720–16724.
- 21. Villa P, Kaufmann SH, Earnshaw WC (1997) Caspases and caspase inhibitors. Trends Biochem Sci 22: 388–393.
- 22. Duex JE, Comeau L, Sorkin A, Purow B, Kefas B (2011) Usp18 regulates epidermal growth factor (EGF) receptor expression and cancer cell survival via microRNA-7. J Biol Chem 286: 25377–25386.
- 23. Chakrabarti M, Khandkar M, Banik NL, Ray SK (2012) Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells. Brain Res 1454: 1–13.
- 24. Xiong S, Zheng Y, Jiang P, Liu R, Liu X, et al. (2011) MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci 7: 805–814.
- 25. Rai K, Takigawa N, Ito S, Kashihara H, Ichihara E, et al. (2011) Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther 10: 1720–1727.
- 26. Jiang L, Liu X, Chen Z, Jin Y, Heidbreder CE, et al. (2010) MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J 432: 199–205.
- 27. Ekhterae D, Lin Z, Lundberg MS, Crow MT, Brosius FC 3rd, et al. (1999) ARC inhibits cytochrome c release from mitochondria and protects against hypoxia-induced apoptosis in heart-derived H9c2 cells. Circ Res 85: e70–77.
- 28. Fleury S, Simeoni E, Zuppinger C, Deglon N, von Segesser LK, et al. (2003) Multiply attenuated, self-inactivating lentiviral vectors efficiently deliver and express genes for extended periods of time in adult rat cardiomyocytes in vivo. Circulation 107: 2375–2382.
- 29. Ji ES, Yue H, Wu YM, He RR (2004) Effects of phytoestrogen genistein on myocardial ischemia/reperfusion injury and apoptosis in rabbits. Acta Pharmacol Sin 25: 306–312.
- 30. Qi J, Qiao Y, Wang P, Li S, Zhao W, et al. (2012) microRNA-210 negatively regulates LPS-induced production of proinflammatory cytokines by targeting NF-κB1 in murine macrophages. FEBS Lett 586: 1201–1207.
- 31. Mohanty I, Arya DS, Gupta SK (2006) Effect of Curcuma longa and Ocimum sanctum on myocardial apoptosis in experimentally induced myocardial ischemic-reperfusion injury. BMC Complement Altern Med 6: 3.
- 32. Bushati N, Cohen SM (2007) microRNA functions. Annu Rev Cell Dev Biol 23: 175–205.
- 33. Yang B, Lin H, Xiao J, Lu Y, Luo X, et al. (2007) The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13: 486–491.
- 34. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, et al. (2007) Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316: 575–579.
- 35. Xu C, Lu Y, Pan Z, Chu W, Luo X, et al. (2007) The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 120: 3045–3052.
- 36. Wang JX, Jiao JQ, Li Q, Long B, Wang K, et al. (2011) miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med 17: 71–78.
- 37. Rane S, He M, Sayed D, Vashistha H, Malhotra A, et al. (2009) Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 104: 879–886.
- 38. Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, et al. (1998) Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 12: 806–819.
- 39. Liu J, Mao W, Ding B, Liang CS (2008) ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol 295: H1956–1965.
- 40. Choi JY, Kim BM, Kim YJ, Woo HD, Chung HW (2007) Hypoxia/reoxygenation-induced cytotoxicity in cultured human lymphocytes. Biochem Biophys Res Commun 352: 366–371.